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Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common human life-threatening monogenic disor-
ders. The disease is characterized by bilateral, progressive renal cystogenesis and cyst and kidney enlargement, often leading 
to end-stage renal disease, and may include extrarenal manifestations. ADPKD is caused by mutation in one of two genes, 
PKD1 and PKD2, which encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively. PC2 is a non-selective cation chan-
nel permeable to Ca2+, while PC1 is thought to function as a membrane receptor. The cyst cell phenotype includes increased 
proliferation and apoptosis, dedifferentiation, defective planar polarity, and a secretory pattern associated with extracellular 
matrix remodeling. The two-hit model for cyst formation has been recently extended by the demonstration that early gene 
inactivation leads to rapid and diffuse development of renal cysts, while inactivation in adult life is followed by focal and late 
cyst formation. Renal ischemia/reperfusion, however, can function as a third hit, triggering rapid cyst development in kidneys 
with Pkd1 inactivation induced in adult life. The PC1-PC2 complex behaves as a sensor in the primary cilium, mediating signal 
transduction via Ca2+ signaling. The intracellular Ca2+ homeostasis is impaired in ADPKD, being apparently responsible for 
the cAMP accumulation and abnormal cell proliferative response to cAMP. Activated mammalian target for rapamycin (mTOR) 
and cell cycle dysregulation are also significant features of PKD. Based on the identification of pathways altered in PKD, a 
large number of preclinical studies have been performed and are underway, providing a basis for clinical trials in ADPKD and 
helping the design of future trials.
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Autosomal dominant polycystic kidney disease (ADPKD) 
is the most common monogenic kidney disease, affecting 
all races. Though most patients seek medical attention due 
to its renal manifestations, ADPKD is a systemic disorder, 
including a variety of extrarenal abnormalities, which may be 
translated into cystic or non-cystic phenotypes (1). While the 
cystic manifestations are characterized by age-dependent 
occurrence of bilateral, multiple renal cysts and cysts that 
may be present in the liver, seminal vesicles, pancreas, 
arachnoid membrane, and spinal meninges, the noncystic 
alterations include vascular anomalies mainly represented 
by intracranial aneurysms and dolichoectasias, aortic root 
dilatation and mitral valve prolapse, as well as abdominal 
wall hernias and colon diverticula (2).
Epidemiology and natural history
ADPKD affects 1:400 to 1:1000 people and is associated 
with virtually complete penetrance. Its clinical manifestations 
usually appear in the 3rd to 4th decade of life, although in 
1-2% of the cases they are seen in infancy or early childhood. 
Only half of the patients reach the age of 58 years without 
end-stage renal disease (ESRD). The disease, in fact, ac-
counts for 4.4% or more of patients in renal replacement 
therapy worldwide, being the third main cause of ESRD if 
each type of glomerulopathy is considered individually.
The severity of the disease, the age of onset of ESRD, 
and the extrarenal manifestations vary widely among af-
fected individuals. Factors related to a higher rate of renal 
disease progression, in turn, include PKD1 (polycystic 
kidney disease 1) as the mutated locus, increased kidney 
size and growth rate (3), systemic hypertension, early onset 
of hematuria, proteinuria, and possibly male gender for 
ADPKD1. In addition to the loss of renal function, patients 
may also develop other kidney-related manifestations, 
mainly represented by hypertension, chronic abdominal 
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or flank pain, nephrolithiasis, hematuria, concentration 
dysfunction, cyst infection, non-cystic urinary tract infection, 
and cyst hemorrhage.
Pathology
Cyst growth is a gradual process that can lead to the 
formation of enormous cystic kidneys in ADPKD, as well 
as to a markedly enlarged liver (Figure 1). Fluid-filled cysts 
of sizes that can vary from millimeters to more than 10 cm 
are distributed throughout the renal parenchyma, though 
non-cystic areas can be observed in young patients. The 
cyst fluid may be clear or cloudy, watery or thick. Previous 
cystic bleeding can turn the fluid dark due to blood degra-
dation, and often cyst walls can evolve with calcifications.
Cyst formation is a focal process in ADPKD, and reports 
based on human kidney microdissection suggest that they 
are derived from only 1 to 2% of the nephrons. Interestingly, 
after reaching a ~2 mm in diameter, the cyst tends to dis-
connect from the originating tubule. While cysts may arise 
from all segments in ADPKD, apparently those derived from 
collecting ducts appear in higher numbers and are larger 
than the ones of other origins. Most of the cysts are lined 
by a single layer of poorly differentiated epithelial cells, 
though a minority of them can be lined by a significantly 
hyperplastic epithelium. Interstitial inflammation, in turn, is 
usually observed and can lead to cyst-surrounding fibrosis 
in advanced ADPKD kidneys.
Genetics
ADPKD is a genetically heterogeneous disorder caused 
by mutations in one of two genes: PKD1 (located on 
16p13.3) and PKD2 (polycystic kidney disease 2, mapped 
to 4q21). Although some unlinked families have been re-
ported, further analysis of one of them has revealed bilineal 
inheritance of PKD1 and PKD2 heterozygous mutations, 
making uncertain the existence of a third ADPKD locus (4). 
Mutations in the PKD1 gene are responsible for ~85% of 
the disease cases, whereas mutations in PKD2 account 
for ~15% of them. It should be noted that, while the renal 
and extrarenal manifestations are similar in both genetic 
forms, when caused by mutations in PKD1 the disease is 
associated with a more severe clinical course than when 
caused by mutations in PKD2 (5). This difference seems 
to be dependent on the development of a larger number 
of cysts early in life in ADPKD1, and not on a higher cyst 
growth rate (6).
The PKD1 and PKD2 genes
PKD1 includes 46 exons distributed throughout a ~52-
kb genomic segment. The gene gives rise to a 14.2-kb 
mRNA, with an open reading frame of ~12.9 kb (7). An 
interesting feature of PKD1 is the fact that its 5’ portion is 
positioned in a region duplicated several times on chromo-
some 16, making its distinction from highly homologous 
pseudogenes a relatively complex process at the patient 
level. PKD2, on the other hand, spans a ~68-kb genomic 
region and comprises 15 exons. This gene encodes a 
5.4-kb transcript that encompasses a 2.9-kb open read-
ing frame (8).
Hundreds of different mutations in both genes can cause 
ADPKD. While most of the pathogenic mutations lead to 
truncation of the respective gene product, a considerable 
number of mutations are missense.
Figure 1. Autosomal dominant polycystic kidney disease (ADPKD). A, A 39-year-old ADPKD female patient with enlarged, polycystic 
kidneys and liver; computed tomography with iodinated contrast, showing multiple hepatic (arrows) and renal cysts (arrowheads) of 
variable sizes. B, A 32-year-old male patient with ADPKD; magnetic resonance with gadolinium contrast, displaying bilateral multiple 
cysts (arrowheads) distributed throughout the kidneys.
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Phenotype variability and genotype-phenotype 
correlations
ADPKD shows significant clinical variability. This is ob-
served not only among families but also among members 
of the same family, in whom the germline mutation is the 
same. The cyst formation in the kidneys, moreover, consists 
of a focal process. In addition to effects associated with the 
locus involved in the disease (5), the influence of modifier 
loci and the involvement of environmental factors seem to 
also explain the observed variation. Mosaicism is described 
as another cause of phenotypic variability within a family, 
being a potential modulator of disease severity. Comparative 
analysis between siblings and monozygotic twins supports 
indeed the influence of modifier genes on the progression of 
renal disease. Furthermore, the increased risk of recurrence 
of early-onset ADPKD in affected families is suggestive of 
a common family background for modifier genes for early 
and severe phenotype. Variants in other genes associated 
with renal cystic diseases might contribute to this process. 
Contiguous deletion of the adjacent genes PKD1 and TSC2 
(one of the loci mutated in tuberous sclerosis), in fact, leads 
to early-onset PKD associated with clinical manifestations 
of tuberous sclerosis. In the search for other potential 
ADPKD modifier genes, the angiotensin-I-converting en-
zyme I/D polymorphism was analyzed but most investigators 
did not find association with early progression to ESRD. 
It is expected, however, that analyses of quantitative trait 
loci may make a significant contribution to this process. 
Finally, based on the molecular mechanism that underlies 
cystogenesis in ADPKD that will be discussed in this review, 
the frequency and the time in life when somatic mutations 
occur in PKD1/PKD2 appear to also be critical for the course 
of renal disease.
The nature of the germline mutation does not markedly 
correlate with the disease phenotype in either ADPKD1 or 
ADPKD2. Also, no clear correlations were observed for the 
location of PKD2 mutations. The position of PKD1 mutations, 
however, was shown to be relevant: patients with mutations 
in the 5’ region of the gene were associated with an earlier 
onset of ESRD and a higher prevalence of intracranial 
aneurysms than patients with mutations positioned at the 
3’ portion of PKD1. A recent study, moreover, has reported 
the existence of hypomorphic or incompletely penetrant 
PKD1 alleles (9). While one of these alleles may determine 
the development of mildly cystic kidneys, the combination 
of two of them can lead to classical to severe phenotypes 
and association with an inactivating allele may result in 
early-onset ADPKD. 
Polycystins 1 and 2, the PKD1 and PKD2 
gene products
The PKD1 gene encodes polycystin-1 (PC1), a large 
integral membrane glycoprotein with 4303 amino acids (aa) 
and an estimated molecular mass of ~460 kDa (Figure 2). 
This protein contains a >3000-aa extracellular portion with 
a complex combination of domains (Figure 2) that support 
protein-protein and protein-carbohydrate interactions. Six-
teen immunoglobin-like domains named PKD repeats are 
part of this set, being followed by a receptor for egg-jelly 
(REJ) domain and a G-protein-coupled receptor proteolytic 
site (GPS). While the PKD repeats are apparently important 
for molecular interactions and the REJ domain appears to 
play significant regulatory roles, the GPS domain is likely to 
be involved in the process of PC1 activation. This cleavage 
occurs immediately before the first transmembrane (TM) 
domain, resulting in N- and C-terminal fragments. PC1 also 
includes 11 TM domains and a short 197-aa intracellular 
C-terminus. This intracytoplasmic tail contains a coiled-
coil domain and a G-protein-binding domain, playing an 
essential role in signal transduction, as well as an amino-
acid sequence that may contribute to its ubiquitin-mediated 
degradation. Altogether, the PC1 structural features predict 
the protein to function as a receptor and that it may also 
act as an adhesion molecule, mediating cell-cell and cell-
extracellular matrix interactions.
Polycystin-2 (PC2), the PKD2 gene product, is also an 
integral membrane glycoprotein (Figure 2). This ~110-kDa 
protein is formed by 968 aa and is predicted to contain six 
TM domains and intracytoplasmic N- and C-termini (Figure 
1). Interestingly, PC2 shows homology to the last six TM 
domains of PC1, and PC1 and PC2 comprise a subfamily 
of transient receptor potential (TRP) channels. The PC2 
N-terminus includes a dimerization domain and a cilium-
targeting motif (10). Its C-terminal tail, in turn, contains an 
EF-hand calcium-binding motif and a coiled-coil domain re-
sponsible for protein-protein interactions. PC2, also referred 
to as TRPP2, and PC1 (TRPP1) physically interact by their 
C-termini, a binding process involving the PC1 coiled-coil 
domain as well as residues present in a PC2 coiled-coil. 
PC2 is a non-selective cation channel permeable to Ca2+ 
whose activity is regulated by PC1, a process that constitutes 
the polycystin-signaling complex. This physical interaction 
is thought, therefore, to play a key role in intracellular Ca2+ 
homeostasis. In addition, both polycystins have been shown 
to interact with a number of different proteins. It must be 
noted, then, that the outlined features are consistent with 
multifunctional roles for PC1 and PC2.
PC2 is mainly expressed in the endoplasmic reticu-
lum (ER), but different studies have shown that it is also 
found in the plasma membrane, primary apical cilium, 
centrosome, and mitotic spindles. PC1, in turn, shares the 
localization with PC2 in the primary cilium, plasma mem-
brane and potentially in the ER. In mature renal tubules, 
PC1 is expressed in the basolateral membrane at sites 
of cell-cell interactions, in junctional structures identified 
as desmosomes and adherens junctions. A C-terminal 
fragment has also been detected in the cell nucleus (11). 
PC1 has been found, moreover, in cytoplasmic vesicles. 
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Interestingly, PC1 and PC2 have been abundantly found in 
a fraction of urine exosomes. While PC2 shows significant 
expression during development and in the mature kidney, 
PC1 expression is highest during kidney development but 
low in the adult kidney.
The PC2 subcellular transport and localization are 
regulated by phosphorylation processes and interaction 
with adapter proteins. Phosphorylation by casein kinase 
2 can lead it to bind to phosphofurin acidic cluster sorting 
protein-2 (PACS-2), a connector protein bound to COPI, or 
to phosphofurin acidic cluster sorting protein-1 (PACS-1), 
a connector molecule bound to activator protein 1 (AP-1) 
(12). While the physical interaction with PACS-2 mediates 
its trafficking to the ER, its binding to PACS-1 takes it to 
the Golgi/trans-Golgi network. PC2 dephosphorylation by 
protein phosphatase 2A, on the other hand, can release it 
from these interactions and translocate PC2 to the plasma 
membrane. It must be mentioned that translocation of PC2 
to the plasma membrane is also mediated by its binding to 
PC1 (13). A recent study, in turn, suggests that the localiza-
tion of PC1 at the plasma membrane is stimulated by PC2 
and by cleavage at the GPS (14). 
PC1 cleavage: structural basis and biological 
implications
The PC1 cleavage capacity and the generation of an 
N-terminal fragment reflect relevant and specific functional 
properties. While the N- and C-terminal fragments remain 
tethered after cleavage at the GPS domain, they may detach 
depending on appropriate stimulation. In recent years, a 
series of observations has defined the functional particu-
larities and biological implications related to appropriate 
GPS-mediated PC1 cleavage. While mice homozygous 
for Pkd1 null mutations die prenatally with massively cystic 
kidneys, pancreatic cysts, skeletal defects (15), and cardiac 
Figure 2. Domain structure of polycystin-1 and polycystin-2. The protein domains are identified in the figure. ER = endoplasmic reticu-
lum; GPS = G-protein-coupled receptor proteolytic site; LDL-A = low-density lipoprotein A; PLAT = polycystin-1, lipooxygenase, alpha 
toxin; REJ = receptor for egg-jelly; WSC = cell-wall and stress-response component. 
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and vascular abnormalities, homozygotes for a mutation 
that prevents PC1 cleavage but keeps the expression of 
its non-cleavable form develop a postnatal distal nephron 
cystic phenotype (16). This renal cystic phenotype, in turn, 
is rapidly progressive, leading to significantly enlarged kid-
neys, loss of renal function, and death of the vast majority 
of animals by 1 month of age. These findings suggest that 
the non-cleavable form of PC1 is critical for embryogenesis, 
whereas the protein cleavage is essential for postnatal de-
velopment and maintenance of distal nephron segments.
Different studies support the migration of a PC1 C-
terminal fragment to the cell nucleus. According to one of the 
models, a mechanical stimulus upon primary cilia promotes 
cleavage of the protein intracytoplasmic terminus, releasing 
a fragment with a nuclear localization motif (17). Once in 
the nucleus this fragment binds β-catenin, leading to the 
inhibition of the Wnt signaling canonical pathway. The other 
model suggests that, under regular luminal fluid flow, PC1 
retains the non-activated signal transducer and activator 
of transcription (STAT6) in the cilia (11). In the absence of 
tubular fluid flow, however, the PC1 C-tail is cleaved, releas-
ing a fragment that includes its final portion. This fragment 
then interacts with STAT6 and a co-activator, promoting an 
increase in transcription in the nucleus.
Pathogenesis of autosomal dominant 
polycystic kidney disease
Mechanisms involved in cyst formation 
Analysis of DNA samples extracted from individual 
cyst-lining epithelia of affected kidneys provided essential 
elements for the processes of elucidating the molecular 
basis of cystogenesis and explaining disease variability (18). 
These studies revealed that ADPKD cysts are monoclonal 
and suggested that, although the disease inheritance pattern 
is dominant, the mechanism of cyst formation in ADPKD is 
recessive at the cellular/molecular level. According to this 
two-hit model, the germline mutation constitutes the first 
hit, while the second event is represented by a somatic 
mutation in the previously normal allele. Subsequent studies 
have shown that this model applies to both ADPKD1 and 
ADPKD2, as well as to renal and liver cysts.
Genetically modified orthologous mouse models of 
ADPKD supported the proposed model. Null homozygosity 
for Pkd1 or Pkd2 - the mouse orthologues of PKD1 and 
PKD2 - resulted, indeed, in severe cystic formation and 
embryonic lethality (15,19). Pkd1 or Pkd2 heterozygotes, on 
the contrary, developed only a few cysts later in life, mainly 
in the liver. It must be pointed out, however, that cyst forma-
tion may occur even in the absence of complete inactivation 
of Pkd1, since mice with two Pkd1 hypomorphic alleles 
developed renal cysts in the presence of decreased levels 
of PC1 (20). These mice with reduced PC1 expression, 
however, were perinatally viable. Interestingly, compound 
heterozygous Pkd2WS25/- mice, carrying a Pkd2 allele that 
is prone to genomic rearrangement and consequent gen-
eration of a null allele, are born live but develop severely 
polycystic kidneys during adulthood (19). Finally, a chimeric 
mouse model generated by aggregation of Pkd1-/- embry-
onic stem cells to Pkd1+/+ LacZ ROSA26 morulae survived 
beyond one month (21). In this case, although the cysts 
were initially mosaics containing Pkd1-/- and Pkd1+/+ cells, 
over time the cell content gradually became predominantly 
Pkd1-/-. It should be mentioned, however, that alternative 
Pkd1 and Pkd2 dosage mechanisms also appear to lead 
to cystogenesis. Indeed, a Pkd1 transgenic mouse model, 
characterized by Pkd1 overexpression, developed renal 
cysts (22). A generated Pkd2-overexpressing transgenic 
mouse also developed renal cysts, as well as increased 
cell proliferation, apoptosis and v-raf murine sarcoma viral 
oncogene homolog B1 (B-Raf)-dependent extracellular 
signal-regulated protein kinase (ERK) activation (23).
The mechanism of cyst formation in ADPKD, however, 
has been comprehensively analyzed in recent years, im-
proving the originally proposed two-hit model. Induced 
conditional knockout models have allowed, indeed, to 
evaluate in detail the effect of time on Pkd1 inactivation. 
According to a key study, when Pkd1 inactivation occurred 
before P13 the mice developed a rapidly progressive renal 
cystic phenotype, whereas later inactivation was followed 
by very late cyst formation (24). These findings suggest 
that the biological consequences of Pkd1 inactivation are 
determined by a developmental switch that signals the end 
of the kidney maturation process. Along this line, the cyst-
forming effect of kidney-specific inactivation of Kif3a, a gene 
that encodes an intraflagellar transport motor protein, was 
also dependent on the time when inactivation was induced 
(25). When occurring at birth, Kif3a inactivation led to the 
loss of the apical primary cilium and a rapid renal cyst for-
mation, while when induced in adulthood the inactivation 
determined loss of primary cilia but not a rapid development 
of cysts. Another study reported that the induction of Pkd1 
inactivation in newborn mice led to fast and massive renal 
cyst formation, while the induction of gene inactivation in 
adult animals was followed by a considerably mild cystic 
phenotype (20). These investigators suggested that Pkd1 
deficiency does not initiate sufficient autonomous cell prolif-
eration for significant cyst formation. In a context of low cell 
proliferation, therefore, as observed in the adult kidney, the 
inactivation of Pkd1 would not meet the cell environment 
required for rapid and diffuse cystogenesis. 
In a more recent study, Takakura et al. (26) demonstrated 
in an induced knockout model that inactivation of Pkd1 in 
the 5th week of life resulted in the formation of focal cysts 
6 to 9 weeks after knockout induction, while Pkd1 inactiva-
tion induced in the 1st week of life was accompanied by a 
massive development of cysts 6 weeks after gene inacti-
vation. These findings corroborate previous observations, 
supporting the hypothesis that inactivation of Pkd1 would 
not be sufficient to initiate the necessary cell proliferation 
Pathogenesis of autosomal dominant polycystic kidney disease 611
www.bjournal.com.br Braz J Med Biol Res 44(7) 2011
for significant cyst formation in the adult kidney. These data 
led the investigators to propose that the rapid development 
of cysts in the mature kidney might require a third hit in ad-
dition to the inactivation of both Pkd1 alleles. The nature of 
this extra blow, in turn, could be genetic or nongenetic. A 
subsequent study from the same group was able to prove 
this point, showing that renal ischemia/reperfusion (IR) can 
behave as a third hit for cyst formation in adult kidneys (27). 
Mice submitted to Pkd1 inactivation at the age of 5 weeks 
and to unilateral renal IR at 8 weeks had their kidneys 
analyzed at 12-14 weeks. This analysis revealed that the 
post-ischemia kidneys were significantly cystic, a phenotype 
that was not observed in the kidneys not submitted to IR. 
Working with another Pkd1-deficiency model, Bastos et al. 
(28) have also shown an additional-hit effect of IR. In this 
case, Pkd1-haploinsufficient mice submitted to renal IR de-
veloped microcysts in their kidneys 6 weeks after the insult, 
alterations not observed in wild-type animals exposed to the 
same aggression. It was not analyzed, however, whether the 
cells forming microcysts in this model had both Pkd1 alleles 
mutated or not. At present, therefore, most investigators agree 
with the proposed model whereby IR may represent a third 
hit in mature kidneys with Pkd1 inactivation, reactivating 
kidney developmental programs and cell proliferation that 
can create the cellular environment required for rapid and 
diffuse cyst formation.
Abnormalities in planar cell polarity (PCP) have also 
been proposed to participate in cyst formation and growth, 
by perturbing the process of organized epithelial cell division 
along the longitudinal axis, necessary for tubule formation 
and elongation (29,30). A recent report, however, concluded 
that the loss of oriented cell division is not sufficient to initiate 
cyst formation (31). This study with Pkd1 and Pkd2 mutated 
mouse models revealed that pre-cystic cells did not show 
lack of oriented division while they lost it after the initiation 
of tubular dilatation. Homozygous mice for a mutation in 
Pkhd1, the orthologue of the human PKHD1 gene (mutated 
in autosomal recessive polycystic kidney disease), in turn, 
lost oriented cell division, but did not progress to renal cyst 
formation. These observations indicate that disoriented cell 
division is not required to start cystogenesis and is insufficient 
to lead to renal cysts in the mentioned animal models. PCP 
defects, therefore, seem to contribute to cystic growth, but 
are not the primary event that triggers cystogenesis. 
Cellular and transport abnormalities 
The ADPKD cyst-lining epithelial cells are characterized 
by high rates of proliferation and apoptosis, dedifferentia-
tion, planar polarity defects, and a secretory behavior (1). 
Extracellular matrix remodeling is also part of this phenotype. 
Several findings support essential roles for the polycystins 
in the control of cell proliferation and in the maintenance 
of a differentiated phenotype of renal tubular epithelium. 
In support to those findings, the reduction of PC1 or PC2 
below a critical level is accompanied by an abnormal cellular 
phenotype, characterized by increased cell proliferation and 
apoptosis, disturbed planar cell polarity, extracellular matrix 
alterations, and a phenotypic change in salt and fluid transport 
from a reabsorptive to a secretory pattern. The PC1 and PC2 
subcellular expression profiles, in turn, are consistent with 
these mediatory roles.
Unlike normal collecting duct principal cells, in cystic 
epithelium Cl- is secreted, being driven across the baso-
lateral membrane by a Na+K+2Cl- cotransporter, a process 
that follows the gradient established by Na+K+ATPase. Its 
exit across the apical membrane, in turn, occurs through the 
cAMP-triggered Cl- channel cystic fibrosis transmembrane 
conductance regulator (CFTR). Interestingly, the required 
K+ recycling across the basolateral membrane may hap-
pen through the K+ channel KCa3.1 (32). The progressive 
Cl- accumulation within the cyst lumen, therefore, drives 
Na+ and H2O secretion following transepithelial potential 
and osmotic gradients. 
The molecular basis for these phenotypic changes is 
largely unclear, but the recent identification of altered signaling 
pathways in the disease has provided some initial clues. An 
important observation is that PC1 complexes with E-cadherin 
and α-, β- and γ-catenins at cell adherens junctions. Deple-
tion of Ca2+, however, retains PC1 and E-cadherin in the 
cytoplasm, while its repletion is followed by the colocalization 
of both proteins at cell-cell contacts (33). These data support 
a current model whereby PC1 may modulate the intensity 
of cell adhesion by regulating the formation of appropriate 
adherens junctions. In this context, it is key to note that in 
ADPKD the PC1/E-cadherin complex is disrupted.
PC1 and PC2 are also expressed in endothelium and 
vascular smooth muscle cells. These findings support the 
observed endothelial dysfunction and reduced nitric oxide 
generation in ADPKD patients, as well as an increased con-
tractile response of the arterial vasculature in Pkd2+/- mice 
(34). A more recent study, in addition, showed that polycystins 
play a complex role in the maintenance of vascular integrity 
and that Pkd1 and Pkd2 are necessary for the normal de-
velopment of the placenta in mice (35). 
The fact that the polycystins participate in several cell 
signaling pathways makes the process of elucidating these 
molecular mechanisms a complex task. In spite of this sce-
nario, some interventions anchored on alterations of recog-
nized pathways have been successful in blocking or slowing 
the cystic kidney phenotype in animal models of polycystic 
kidney disease, orthologous and nonorthologous to human 
ADPKD. Such signaling pathways will be discussed in the 
following sections.
Ciliary dysfunction and abnormal intracellular 
Ca2+/cAMP signaling 
PC1 and PC2 have been shown to colocalize in the 
primary cilium, an apical sensory organelle bulged to the 
lumen in renal tubular epithelial cells. The PC1-PC2 complex 
is thought to function as a mechano- or chemosensor in the 
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cilia, translating extracellular stimuli into Ca2+ influx through 
PC2. This initial influx triggers significant Ca2+ release from 
intracellular stores, which modulates biological processes 
such as cell proliferation, differentiation, apoptosis, and gene 
expression. The ryanodine and the inositol 1,4,5-triphosphate 
receptors seem to participate in the PC2-related effects on 
the cytoplasmic Ca2+ level (36,37). It is currently admit-
ted that PC2 in the ER participates in intracellular Ca2+ 
homeostasis. A recent study suggests that interaction with 
syntaxin 5 inactivates PC2, preventing Ca2+ leakage from 
the ER (38). The Ca2+ release from intracellular stores is 
reduced in the settings of PC2 absence, haploinsufficiency 
or overexpression. Cyst cells, therefore, show defective Ca2+ 
signaling in response to fluid flow-dependent ciliary bend-
ing and diminished ER Ca2+ stores, as well as decreased 
intracellular Ca2+ concentration in some circumstances. In 
this context, there is a defective homeostasis of intracellular 
Ca2+ in ADPKD, which apparently leads to intracellular ac-
cumulation of cAMP (Figure 3) (1). This reduced activity of 
the polycystin complex and consequent decrease in intracel-
lular Ca2+ concentration, in fact, stimulates Ca2+-inhibitable 
adenylyl cyclase 6 and inhibits Ca2+/calmodulin-dependent 
phosphodiesterase 1, favoring the intracellular generation 
and accumulation of cAMP. Interestingly, the myocyte en-
hancer factor 2C (MEF2C) and histone deacetylase were 
found to be targets of the fluid stress sensing related to the 
PC1-PC2 complex in mouse kidney epithelial cells. Kidney-
specific Mefc2 knockout, in fact, determined significant tubule 
dilatation and renal cysts (39).
In contrast to normal kidney epithelial cells, in which 
cAMP inhibits proliferation, ADPKD cells present an aberrant 
proliferative response to cAMP. The intracellular accumulation 
of cAMP in PKD cells, in fact, is followed by the recruitment 
and phosphorylation of a series of proteins and activates the 
mitogen-activated protein kinase/ERK (MAPK/ERK) pathway 
(Figure 3), promoting cell proliferation and Cl- and fluid secre-
tion, processes that act on cyst growth. In support to these 
findings, transfection of collecting duct principal cells with a 
dominant negative construct of the PC1 C-terminus led to 
cAMP-stimulated proliferation and activation of B-Raf and 
ERK, a process that was inhibited by a Ca2+ ionophore (40). 
The process of lowering intracellular Ca2+ in wild-type cells, 
in addition, triggers the abnormal proliferative response to 
cAMP (40). Procedures that promoted an increase in intra-
cellular Ca2+ in human autosomal dominant and autosomal 
recessive polycystic kidney disease (ADPKD and ARPKD) 
cells, moreover, were effective in returning them to a normal 
proliferation phenotype (41).
Additional signaling pathways altered in ADPKD
Different lines of evidence demonstrate a direct link be-
tween polycystins and cell cycle regulation. A classical study 
reported that activation of PC1, following a PC2-dependent 
process, activates JAK2, leading to phosphorylation and 
formation of STAT1 homodimers. These dimers, in turn, 
translocate to the cell nucleus and bind to the p21 gene pro-
moter, up-regulating its product (42). The p21 up-regulation 
inhibits Cdk2 activity, determining cell cycle arrest in G0/G1. 
This mechanism may significantly contribute to the inhibi-
tory effect of PC1 on cell proliferation. PC1 also contains a 
conserved trimeric G-protein activation domain, leading G-
protein subunits to mediate the PC1-related activation of the 
c-Jun N-terminal kinase (JNK) and AP-1 transcription factor 
(43). The alteration in AP-1 activity reported in ADPKD, in 
fact, may contribute to the abnormalities in cell differentiation, 
proliferation and apoptosis observed in this disease. Other 
investigators have reported that the activation of JNK by PC1 
occurs via protein kinase C-alpha (PKC-α). A recent study, 
in turn, revealed that the activator of G-protein signaling 3 
may regulate Gα subunit function in a receptor-independent 
manner, modulating the function of epithelial cells in PKD. 
PC1 has been reported to favor the stabilization of the 
tuberin-hamartin complex, inhibiting mammalian target for 
rapamycin (mTOR) activity. This process can be secondary 
to the PC1 interaction with the TSC2 gene product, tuberin, 
at the plasma membrane level, preventing its phosphoryla-
tion by protein kinase B (Akt) and consequently allowing the 
tuberin-hamartin complex to inhibit mTOR. Alternatively, PC1 
can reduce tuberin ERK-dependent phosphorylation (44), 
keeping the tuberin-hamartin complex stable. In ADPKD, 
the disruption of such mechanisms activates mTOR and 
promotes cell proliferation (Figure 3). PC2, in turn, can also 
decrease cell proliferation by interacting with pancreatic eIF2α 
kinase (PERK) at the ER level, promoting phosphorylation of 
the translation initiation factor 2 alpha (eIF2α) (45). The three 
proteins PC2, PERK and eIF2α, in fact, were found to be in 
the same complex. Increased apoptosis is another key feature 
of ADPKD. It is currently admitted that resistance to apoptosis 
induced by PC1 is a process probably dependent on GiCPR 
activation of phosphatidylinositol 3-kinase and Akt.
As previously pointed out, the disruption of PCP ap-
pears to play a role in ADPKD cyst expansion (29,30). 
The molecular basis of these abnormalities in cell division 
orientation has received some clues in the recent years. 
A series of observations have revealed activation of the 
canonical β-catenin-dependent Wnt signaling pathway as 
an early effect of Pkd1 gene disruption (46) and implicate 
both canonical and non-canonical Wnt signaling pathways 
in cyst formation. In agreement with such findings, a more 
recent study has reported increased levels of β-catenin in 
cultured Pkd2-knockout mouse cells (Figure 3). It has not 
been clarified, however, whether this β-catenin increase is 
determined by the absence of PC2 itself or by PC2-depen-
dent PC1 dysregulation. Curiously, it has been shown that 
secreted Frizzled-related protein 4 (sFRP4) is up-regulated 
in ADPKD and in Pkd2-/- mice (47) (Figure 3). The fact that 
it inhibits only part of the components of the canonical Wnt 
signaling pathway probably explains why β-catenin levels 
can increase in PKD.
Two recent studies have shown that Pkd1 and Pkd2 
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haploinsufficiency have a significant impact on the renal cell 
repair response to IR. Such studies revealed an increased 
susceptibility to ischemia/reperfusion insult in Pkd1+/- and 
Pkd2+/- mice compared with their corresponding wild-type 
controls (28,48). Increased cell proliferation, apoptosis, 
inflammation, and late fibrosis were observed in the haplo-
insufficient animals, as well as a lower level of p21 expres-
sion following the IR insult. Progress has also been made 
in the understanding of dysregulation of metalloproteinase 
inhibitor and matrix-degrading enzyme expression. Cyst 
epithelial cells were found to generate large quantities of 
laminin, collagen I and III, transforming growth factor-beta 
(TGF-β) and periostin, which are deposited around the 
cystic structures. Laminin-5 is markedly expressed in the 
extracellular matrix of ADPKD kidneys but not in control 
organs, while ADPKD cells produce and secrete this mol-
Figure 3. Disrupted pathways in polycystic kidney disease (PKD) and points of potential therapeutic intervention with specific agents. 
Agents associated with potential therapeutic interventions are represented in red; ant = antagonist; inh = inhibitor. AC-VI = adenylate 
cyclase 6; Akt = protein kinase B; AMPK = AMP kinase; B-Raf = v-raf murine sarcoma viral oncogene homolog B1; CDK = cyclin-de-
pendent kinase; CFTR = cystic fibrosis transmembrane conductance regulator; EGF = epidermal growth factor; EP2R = E-prostanoid 
receptor 2; ERK = extracellular signal-regulated protein kinase; GSK3 = glycogen synthase kinase 3; IGF1 = insulin-like growth factor 
1; IP3R = inositol 1,4,5-trisphosphate receptor; MAPK = mitogen-activated protein kinase; mTOR = mammalian target for rapamycin; 
PC1 = polycystin-1; PC2 = polycystin-2; PDE = phosphodiesterase; PGE2 = prostaglandin E2; PI3K = phosphatidylinositol 3-kinase; 
PKA = protein kinase A; PLA2 = phospholipase A2; PLCγ = phospholipase C-γ2; R = somatostatin sst2 receptor; Rheb = ras homolog 
enriched in brain; RyR = ryanodine receptor; sFRP4 = secreted Frizzled-related protein 4; TK = tyrosine kinase; TNF-α = tumor necro-
sis factor-α; TSC = tuberous sclerosis proteins tuberin (TSC2) and hamartin (TSC1); V2R = vasopressin V2 receptor; VEGF = vascular 
endothelial growth factor. (Adapted from a schema previously used by Vicente E. Torres and Peter C. Harris, with permission).
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ecule. Laminin-5, moreover, is a significant regulator of 
ADPKD cell proliferation and cyst formation. A recent study 
by Hassane et al. (49) has indicated that TGF-β signaling 
does not play a role in the beginning of cystogenesis, but 
participates significantly during cyst expansion and fibro-
genesis along the progression of ADPKD (49). An analysis 
performed in the PCK rat, a model orthologous to human 
ARPKD, suggests, in addition, that epithelial cells in renal 
cysts develop mesenchymal characteristics in response to 
cyst growth, a process that may contribute to progressive 
kidney fibrosis. 
Preclinical studies and therapeutic 
prospects based on molecular and 
cellular pathogenesis 
A number of preclinical studies based on the pathoge-
netic findings described here were carried out in the past 
decade, trying to prevent PKD development or to slow the 
progression of renal cystic disease. These analyses have 
been performed in animal models orthologous and non-
orthologous to human renal cystic diseases. In this review, 
priority will be given to the results obtained in orthologous 
models. Notably, some of the data have been strong enough 
to justify large clinical trials in ADPKD patients, including 
already concluded, ongoing and planned studies.
Renal cysts originate predominantly from collecting 
ducts in ADPKD, at least in the early stages. In the princi-
pal cells of collecting ducts, the vasopressin/V2 receptor 
system is a major source of cAMP generation. Treatment 
with a V2 receptor antagonist inhibited cyst formation and 
the progression of the polycystic kidney phenotype in the 
PCK rat (50) and in the Pkd2WS25/- mouse (51), support-
ing a central role of cAMP in PKD (Figure 3). A phase-3 
multicenter clinical trial with Tolvaptan, a vasopressin V2 
receptor antagonist, is ongoing in ADPKD patients. Further-
more, the inhibition of vasopressin release by a very high 
water intake in the PCK rat showed a protective effect on 
the renal cystic disorder. In accordance to these findings, 
an antagonist of the endothelin B receptor increased the 
cAMP renal level and worsened the cystic phenotype in 
Pkd2WS25/- mice through a mechanism that apparently 
includes an increased vasopressin action. 
Several effects of somatostatin may hinder cyst develop-
ment both in kidney and liver. These effects include inhibition 
of vasopressin-dependent cAMP generation at the collect-
ing duct level via Gi-protein-coupled receptors, inhibition of 
secretin-dependent cAMP production and fluid secretion in 
cholangiocytes, and reduction of insulin-like growth factor 
1 and vascular endothelial growth factor (VEGF) expres-
sion (Figure 3). The long-acting somatostatin analogue 
octreotide, in fact, improved the cystic renal and liver 
phenotypes of the PCK rat, emphasizing the significance 
of cAMP signaling in PKD (52). Positive results have been 
obtained with octreotide in ADPKD patients with polycystic 
kidneys and liver and in isolated autosomal dominant poly-
cystic liver disease (ADPLD) patients (53), but larger and 
longer clinical trials are required. In support to the Ca2+/
cAMP signaling role in PKD, triptolide, a drug shown to be 
able to release Ca2+ through a process that depends on 
PC2, ameliorated the cystic disease in kidney-specific Pkd1 
conditional knockout mice, attenuated the cystic phenotype 
in Pkd1-/- mice during embryonic life, and blocked prolif-
eration of Pkd1-/- cells (Figure 3). Treatment with a type 2 
calcimimetic, however, did not affect renal cAMP levels or 
cystogenesis in Pkd2WS25/- mice and PCK rats, a finding 
that might be explained by a decrease in extracellular Ca2+ 
or by the lack of Ca2+-sensing receptors in the cortical and 
outer medullary portions of collecting ducts.
Focusing on inhibition of mTOR (Figure 3), recent stud-
ies showed that sirolimus reduced the cystic burden and 
preserved renal function in Pkd1cond/cond:NestinCre mice 
(54), and also reduced the progression of cystic disease 
in Pkd2WS25/- mice. The conclusion of a recent clinical trial 
using sirolimus in ADPKD patients with early renal disease, 
however, did not show blockade of kidney growth (55), 
while another large clinical trial with everolimus in ADPKD 
patients with more advanced disease reported diminishment 
in kidney volume increase but no reduction in the rate of 
renal function decline (56). Based on its stimulating effect 
upon AMP-activated protein kinase, metformin can inhibit 
CFTR and inhibit mTOR by phosphorylating tuberin (Figure 
3). Notably, metformin reduced the cystic phenotype in two 
mouse models orthologous to ADPKD1: Pkd1flox/-;Ksp:Cre 
and Pkd1flox/-;pCX:CreER with Cre induction at P9 or P10 
(57). Inhibition of mTOR can also hinder the generation of 
VEGF and suppress its cellular effects. Interestingly, the 
VEGF receptor (VEGFR) inhibitor SU-5416 blocked cyst 
growth in liver but not in kidney in Pkd2WS25/- mice, whereas 
the administration of anti-VEGFR2 antibodies led to the 
formation of renal cysts in early-life CD-1 mice. In a recent 
report, Qin et al. (58) showed that mTOR hyperactivation 
in Pkd1-/- mouse cells occurs due to a lack of appropriate 
ubiquitination and degradation of the hepatocyte growth 
factor (HGF) receptor c-Met following HGF stimulation. 
Treatment of Pkd1-/- kidneys in organ culture with a c-Met 
inhibitor indeed reduced the size and number of cysts. 
A series of drugs that reduce cell proliferation have 
been studied in PKD animal models and have been shown 
to promote improvement of cystic phenotype. Such agents 
include inhibitors of Src kinase, epidermal growth factor 
receptor 1 (Erb-B1) and Erb-B2 tyrosine kinase and MEK 
(Figure 3). Sorafenid, a small molecule Raf inhibitor, inhibits 
cAMP-dependent proliferation and in vitro cyst growth of 
human ADPKD cystic cells. The cyclin-dependent kinase 
inhibitor roscovitine has also been effective by arresting 
the cell cycle, inhibiting apoptosis and regulating transcrip-
tion. This drug has significantly reduced cyst formation and 
attenuated renal disfunction in the juvenile cystic kidneys 
(jck) and congenital polycystic kidney (cpk) mice, two PKD 
Pathogenesis of autosomal dominant polycystic kidney disease 615
www.bjournal.com.br Braz J Med Biol Res 44(7) 2011
animal models non-orthologous to human ADPKD or AR-
PKD (59). Pioglitazone, a peroxisome proliferator-activated 
receptor γ (PPAR-γ) agonist, ameliorated the cardiac de-
fects, decreased renal cystogenesis and increased survival 
in Pkd1-/- embryos, and inhibited kidney and liver cyst 
growth in the PCK rat. Genz-123346, a drug that inhibits 
the accumulation of glucosylceramide, has also shown 
positive results in an animal model orthologous to human 
ADPKD1. Recent studies, furthermore, have reported that 
the inhibitor of histone deacetylase valproic acid reduced 
cyst formation and the rate of renal function decline in a 
Pkd1flox/flox;Pkhd1:Cre mouse model (60). Trichostatin A, 
another histone deacetylase inhibitor, was also capable of 
reducing cyst formation in Pkd2-/- mouse embryos (39).
Turning to transepithelial Cl- and fluid secretion (Fig-
ure 3), CFTR and KCa3.1 inhibitors were tested. CFTR 
inhibition reduced the rate of cyst growth and preserved 
renal function in Pkd1flox/-;Ksp:Cre mice, while the KCa3.1 
inhibitor TRAM-34 inhibited transepithelial Cl- secretion 
stimulated by forskolin in ADPKD cell polarized monolayers 
and cyst formation and growth by ADPKD cells cultured in 
collagen gel.
Tumor necrosis factor-α (TNF-α) is found in the fluid 
of human ADPKD cysts and its mRNA level increases 
progressively with time in the kidneys of the cpk mouse 
cystic model. Intraperitoneal TNF-α injection, moreover, 
leads to cyst formation in Pkd2+/- mice. This pro-cystic 
effect (Figure 3) is corroborated by the observation that 
etanercept, a TNF-α blocker, prevented cyst formation in 
this orthologous animal model. Additional data obtained in 
a human epithelial cell-culture system derived from normal 
and ADPKD kidneys, developed in a three-dimensional gel 
matrix, suggest that prostaglandin E2 (PGE2), present in 
the cyst fluid, binds to apical EP2 receptors and stimulates 
its expression, increasing cAMP production and promot-
ing cystogenesis (Figure 3). EP2 receptor antagonists, 
therefore, may become a potential therapeutic target for 
ADPKD. The cytochrome P450 metabolite of arachidonic 
acid 20-hydroxyeicosatetraenoic (20-HETE) is generated 
in larger amounts in microsomes of the bpk mouse kidney, 
a recessive model non-orthologous to human ARPKD. The 
observation that inhibition of its synthesis by HET-0016 
markedly reduced kidney size and prolonged survival in 
this mouse model suggests that the endogenous metabo-
lite 20-HETE mediates cell proliferation in the formation 
of renal cysts.
Conclusion and Perspectives
The scientific reality regarding ADPKD, therefore, has 
gone through dramatic changes within the past two de-
cades, particularly in recent years. In this new scenario, 
the progressive elucidation of its molecular and cellular 
pathogenesis is substantially extending our understanding 
of biological systems and mechanisms, as well as opening 
promising therapeutic perspectives. The animal and cellular 
models have been playing central roles in this process, 
markedly contributing to the gradual understanding of PKD 
pathogenesis and allowing essential preclinical studies. 
Such knowledge accumulation, in turn, has already led to 
the performance of initial information-based clinical trials. 
The progressive genetic, molecular and cellular sophisti-
cation of biological models will keep defining the scientific 
progress in this field.
Acknowledgments
Research supported by FAPESP (#2009/13926-3 to L.F. 
Onuchic and #2010/10425-0 to A.P. Bastos).
 1. Torres VE, Harris PC. Autosomal dominant polycystic kidney 
disease: the last 3 years. Kidney Int 2009; 76: 149-168.
 2. Pirson Y. Extrarenal manifestations of autosomal dominant 
polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17: 
173-180.
 3. Chapman AB, Guay-Woodford LM, Grantham JJ, Torres 
VE, Bae KT, Baumgarten DA, et al. Renal structure in early 
autosomal-dominant polycystic kidney disease (ADPKD): 
The Consortium for Radiologic Imaging Studies of Polycystic 
Kidney Disease (CRISP) cohort. Kidney Int 2003; 64: 1035-
1045.
 4. Pei Y, Paterson AD, Wang KR, He N, Hefferton D, Watnick T, 
et al. Bilineal disease and trans-heterozygotes in autosomal 
dominant polycystic kidney disease. Am J Hum Genet 2001; 
68: 355-363.
 5. Hateboer N, Dijk MA, Bogdanova N, Coto E, Saggar-Malik 
AK, San Millan JL, et al. Comparison of phenotypes of poly-
cystic kidney disease types 1 and 2. European PKD1-PKD2 
References
Study Group. Lancet 1999; 353: 103-107.
 6. Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, 
Chapman AB, et al. Cyst number but not the rate of cystic 
growth is associated with the mutated gene in autosomal 
dominant polycystic kidney disease. J Am Soc Nephrol 
2006; 17: 3013-3019.
 7. Hughes J, Ward CJ, Peral B, Aspinwall R, Clark K, San 
Millan JL, et al. The polycystic kidney disease 1 (PKD1) 
gene encodes a novel protein with multiple cell recognition 
domains. Nat Genet 1995; 10: 151-160.
 8. Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen 
B, Saris JJ, et al. PKD2, a gene for polycystic kidney disease 
that encodes an integral membrane protein. Science 1996; 
272: 1339-1342.
 9. Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley 
SW, et al. Incompletely penetrant PKD1 alleles suggest a 
role for gene dosage in cyst initiation in polycystic kidney 
disease. Kidney Int 2009; 75: 848-855.
616 A.P. Bastos and L.F. Onuchic
www.bjournal.com.brBraz J Med Biol Res 44(7) 2011
10. Feng S, Okenka GM, Bai CX, Streets AJ, Newby LJ, 
DeChant BT, et al. Identification and functional characteriza-
tion of an N-terminal oligomerization domain for polycystin-2. 
J Biol Chem 2008; 283: 28471-28479.
11. Low SH, Vasanth S, Larson CH, Mukherjee S, Sharma N, 
Kinter MT, et al. Polycystin-1, STAT6, and P100 function in 
a pathway that transduces ciliary mechanosensation and is 
activated in polycystic kidney disease. Dev Cell 2006; 10: 
57-69.
12. Kottgen M, Benzing T, Simmen T, Tauber R, Buchholz B, 
Feliciangeli S, et al. Trafficking of TRPP2 by PACS proteins 
represents a novel mechanism of ion channel regulation. 
EMBO J 2005; 24: 705-716.
13. Hanaoka K, Qian F, Boletta A, Bhunia AK, Piontek K, Tsiokas 
L, et al. Co-assembly of polycystin-1 and -2 produces unique 
cation-permeable currents. Nature 2000; 408: 990-994.
14. Chapin HC, Rajendran V, Caplan MJ. Polycystin-1 surface 
localization is stimulated by polycystin-2 and cleavage at 
the G protein-coupled receptor proteolytic site. Mol Biol Cell 
2010; 21: 4338-4348.
15. Lu W, Shen X, Pavlova A, Lakkis M, Ward CJ, Pritchard L, et 
al. Comparison of Pkd1-targeted mutants reveals that loss 
of polycystin-1 causes cystogenesis and bone defects. Hum 
Mol Genet 2001; 10: 2385-2396.
16. Yu S, Hackmann K, Gao J, He X, Piontek K, Garcia-Gonza-
lez MA, et al. Essential role of cleavage of Polycystin-1 at G 
protein-coupled receptor proteolytic site for kidney tubular 
structure. Proc Natl Acad Sci U S A 2007; 104: 18688-
18693.
17. Lal M, Song X, Pluznick JL, Di Giovanni V, Merrick DM, 
Rosenblum ND, et al. Polycystin-1 C-terminal tail associates 
with beta-catenin and inhibits canonical Wnt signaling. Hum 
Mol Genet 2008; 17: 3105-3117.
18. Qian F, Watnick TJ, Onuchic LF, Germino GG. The molecular 
basis of focal cyst formation in human autosomal dominant 
polycystic kidney disease type I. Cell 1996; 87: 979-987.
19. Wu G, Markowitz GS, Li L, D’Agati VD, Factor SM, Geng L, 
et al. Cardiac defects and renal failure in mice with targeted 
mutations in Pkd2. Nat Genet 2000; 24: 75-78.
20. Lantinga-van Leeuwen I, Dauwerse JG, Baelde HJ, Leon-
hard WN, van de Wal A, Ward CJ, et al. Lowering of Pkd1 
expression is sufficient to cause polycystic kidney disease. 
Hum Mol Genet 2004; 13: 3069-3077.
21. Nishio S, Hatano M, Nagata M, Horie S, Koike T, Tokuhisa 
T, et al. Pkd1 regulates immortalized proliferation of renal 
tubular epithelial cells through p53 induction and JNK activa-
tion. J Clin Invest 2005; 115: 910-918.
22. Thivierge C, Kurbegovic A, Couillard M, Guillaume R, Cote 
O, Trudel M. Overexpression of PKD1 causes polycystic 
kidney disease. Mol Cell Biol 2006; 26: 1538-1548.
23. Park EY, Sung YH, Yang MH, Noh JY, Park SY, Lee TY, et 
al. Cyst formation in kidney via B-Raf signaling in the PKD2 
transgenic mice. J Biol Chem 2009; 284: 7214-7222.
24. Piontek K, Menezes LF, Garcia-Gonzalez MA, Huso DL, 
Germino GG. A critical developmental switch defines the 
kinetics of kidney cyst formation after loss of Pkd1. Nat Med 
2007; 13: 1490-1495.
25. Patel V, Li L, Cobo-Stark P, Shao X, Somlo S, Lin F, et al. 
Acute kidney injury and aberrant planar cell polarity induce 
cyst formation in mice lacking renal cilia. Hum Mol Genet 
2008; 17: 1578-1590.
26. Takakura A, Contrino L, Beck AW, Zhou J. Pkd1 inactivation 
induced in adulthood produces focal cystic disease. J Am 
Soc Nephrol 2008; 19: 2351-2363.
27. Takakura A, Contrino L, Zhou X, Bonventre JV, Sun Y, Hum-
phreys BD, et al. Renal injury is a third hit promoting rapid 
development of adult polycystic kidney disease. Hum Mol 
Genet 2009; 18: 2523-2531.
28. Bastos AP, Piontek K, Silva AM, Martini D, Menezes LF, 
Fonseca JM, et al. Pkd1 haploinsufficiency increases renal 
damage and induces microcyst formation following isch-
emia/reperfusion. J Am Soc Nephrol 2009; 20: 2389-2402.
29. Fischer E, Legue E, Doyen A, Nato F, Nicolas JF, Torres V, et 
al. Defective planar cell polarity in polycystic kidney disease. 
Nat Genet 2006; 38: 21-23.
30. Luyten A, Su X, Gondela S, Chen Y, Rompani S, Takakura A, 
et al. Aberrant regulation of planar cell polarity in polycystic 
kidney disease. J Am Soc Nephrol 2010; 21: 1521-1532.
31. Nishio S, Tian X, Gallagher AR, Yu Z, Patel V, Igarashi P, et 
al. Loss of oriented cell division does not initiate cyst forma-
tion. J Am Soc Nephrol 2010; 21: 295-302.
32. Albaqumi M, Srivastava S, Li Z, Zhdnova O, Wulff H, Itani 
O, et al. KCa3.1 potassium channels are critical for cAMP-
dependent chloride secretion and cyst growth in autosomal-
dominant polycystic kidney disease. Kidney Int 2008; 74: 
740-749.
33. Markoff A, Bogdanova N, Knop M, Ruffer C, Kenis H, Lux P, 
et al. Annexin A5 interacts with polycystin-1 and interferes 
with the polycystin-1 stimulated recruitment of E-cadherin 
into adherens junctions. J Mol Biol 2007; 369: 954-966.
34. Qian Q, Hunter LW, Du H, Ren Q, Han Y, Sieck GC. Pkd2+/- 
vascular smooth muscles develop exaggerated vasocon-
traction in response to phenylephrine stimulation. J Am Soc 
Nephrol 2007; 18: 485-493.
35. Garcia-Gonzalez MA, Outeda P, Zhou Q, Zhou F, Menezes 
LF, Qian F, et al. Pkd1 and Pkd2 are required for normal 
placental development. PLoS One 2010; 5: e12821.
36. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, 
et al. Polycystins 1 and 2 mediate mechanosensation in the 
primary cilium of kidney cells. Nat Genet 2003; 33: 129-
137.
37. Li Y, Wright JM, Qian F, Germino GG, Guggino WB. Polycys-
tin 2 interacts with type I inositol 1,4,5-trisphosphate receptor 
to modulate intracellular Ca2+ signaling. J Biol Chem 2005; 
280: 41298-41306.
38. Geng L, Boehmerle W, Maeda Y, Okuhara DY, Tian X, Yu 
Z, et al. Syntaxin 5 regulates the endoplasmic reticulum 
channel-release properties of polycystin-2. Proc Natl Acad 
Sci U S A 2008; 105: 15920-15925.
39. Xia S, Li X, Johnson T, Seidel C, Wallace DP, Li R. Polycys-
tin-dependent fluid flow sensing targets histone deacetylase 
5 to prevent the development of renal cysts. Development 
2010; 137: 1075-1084.
40. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, 
Grantham JJ, Calvet JP. Calcium restriction allows cAMP 
activation of the B-Raf/ERK pathway, switching cells to 
a cAMP-dependent growth-stimulated phenotype. J Biol 
Chem 2004; 279: 40419-40430.
41. Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace 
DP. Calcium restores a normal proliferation phenotype in 
human polycystic kidney disease epithelial cells. J Am Soc 
Nephrol 2006; 17: 178-187.
42. Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, et 
al. PKD1 induces p21(waf1) and regulation of the cell cycle 
Pathogenesis of autosomal dominant polycystic kidney disease 617
www.bjournal.com.br Braz J Med Biol Res 44(7) 2011
via direct activation of the JAK-STAT signaling pathway in a 
process requiring PKD2. Cell 2002; 109: 157-168.
43. Parnell SC, Magenheimer BS, Maser RL, Zien CA, Frischauf 
AM, Calvet JP. Polycystin-1 activation of c-Jun N-terminal 
kinase and AP-1 is mediated by heterotrimeric G proteins. J 
Biol Chem 2002; 277: 19566-19572.
44. Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek 
KB, et al. Polycystin-1 regulates extracellular signal-regulat-
ed kinase-dependent phosphorylation of tuberin to control 
cell size through mTOR and its downstream effectors S6K 
and 4EBP1. Mol Cell Biol 2009; 29: 2359-2371.
45. Liang G, Yang J, Wang Z, Li Q, Tang Y, Chen XZ. Polycys-
tin-2 down-regulates cell proliferation via promoting PERK-
dependent phosphorylation of eIF2alpha. Hum Mol Genet 
2008; 17: 3254-3262.
46. Happe H, Leonhard WN, van der Wal A, van de Water B, 
Lantinga-van Leeuwen I, Breuning MH, et al. Toxic tubular 
injury in kidneys from Pkd1-deletion mice accelerates cys-
togenesis accompanied by dysregulated planar cell polarity 
and canonical Wnt signaling pathways. Hum Mol Genet 
2009; 18: 2532-2542.
47. Romaker D, Puetz M, Teschner S, Donauer J, Geyer M, 
Gerke P, et al. Increased expression of secreted frizzled-
related protein 4 in polycystic kidneys. J Am Soc Nephrol 
2009; 20: 48-56.
48. Prasad S, McDaid JP, Tam FW, Haylor JL, Ong AC. Pkd2 
dosage influences cellular repair responses following 
ischemia-reperfusion injury. Am J Pathol 2009; 175: 1493-
1503.
49. Hassane S, Leonhard WN, van der Wal A, Hawinkels LJ, 
Lantinga-van Leeuwen I, ten Dijke P, et al. Elevated TGFbe-
ta-Smad signalling in experimental Pkd1 models and human 
patients with polycystic kidney disease. J Pathol 2010; 222: 
21-31.
50. Gattone VH, Wang X, Harris PC, Torres VE. Inhibition of renal 
cystic disease development and progression by a vasopres-
sin V2 receptor antagonist. Nat Med 2003; 9: 1323-1326.
51. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone 
VH. Effective treatment of an orthologous model of auto-
somal dominant polycystic kidney disease. Nat Med 2004; 
10: 363-364.
52. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. 
Octreotide inhibits hepatic cystogenesis in a rodent model of 
polycystic liver disease by reducing cholangiocyte adenos-
ine 3’,5’-cyclic monophosphate. Gastroenterology 2007; 
132: 1104-1116.
53. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li 
X, et al. Randomized clinical trial of long-acting somatostatin 
for autosomal dominant polycystic kidney and liver disease. 
J Am Soc Nephrol 2010; 21: 1052-1061.
54. Shillingford JM, Piontek KB, Germino GG, Weimbs T. Ra-
pamycin ameliorates PKD resulting from conditional inacti-
vation of Pkd1. J Am Soc Nephrol 2010; 21: 489-497.
55. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, 
et al. Sirolimus and kidney growth in autosomal dominant 
polycystic kidney disease. N Engl J Med 2010; 363: 820-
829.
56. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, 
Sommerer C, et al. Everolimus in patients with autosomal 
dominant polycystic kidney disease. N Engl J Med 2010; 
363: 830-840.
57. Takiar V, Nishio S, Seo-Mayer P, King JD Jr, Li H, Zhang L, 
et al. Activating AMP-activated protein kinase (AMPK) slows 
renal cystogenesis. Proc Natl Acad Sci U S A 2011; 108: 
2462-2467.
58. Qin S, Taglienti M, Nauli SM, Contrino L, Takakura A, Zhou 
J, et al. Failure to ubiquitinate c-Met leads to hyperactivation 
of mTOR signaling in a mouse model of autosomal dominant 
polycystic kidney disease. J Clin Invest 2010; 120: 3617-
3628.
59. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, 
Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine 
polycystic kidney disease with CDK inhibitor roscovitine. 
Nature 2006; 444: 949-952.
60. Cao Y, Semanchik N, Lee SH, Somlo S, Barbano PE, Coif-
man R, et al. Chemical modifier screen identifies HDAC 
inhibitors as suppressors of PKD models. Proc Natl Acad 
Sci U S A 2009; 106: 21819-21824.
